Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8982024 | 0.83 | MEN1 (0.46) | CYP3A4MEN1KMT2ALMNATDP1 | |
| SCHEMBL244687 | 0.79 | LMNA (0.43) | CYP3A4MEN1KMT2ALMNATDP1 | |
| SCHEMBL9025866 | 0.79 | LMNA (0.67) | CYP3A4MEN1KMT2ALMNATDP1 | |
| SCHEMBL1403728 | 0.78 | LMNA (0.42) | CYP3A4MEN1KMT2ALMNATDP1 | |
| SCHEMBL3627279 | 0.78 | CD38 (0.42) | CYP3A4MEN1KMT2ALMNATDP1 | |
| SCHEMBL9522386 | 0.74 | CYP1A2 (0.54) | CYP3A4MEN1KMT2ALMNATDP1 | |
| SCHEMBL20357191 | 0.74 | LMNA (0.40) | CYP3A4MEN1KMT2ALMNATDP1 | |
| SCHEMBL23094492 | 0.73 | CYP11B1 (0.43) | CYP3A4MEN1KMT2ALMNATDP1 | |
| SCHEMBL5192586 | 0.73 | CD38 (0.54) | CYP3A4MEN1KMT2ALMNATDP1 | |
| SCHEMBL3273198 | 0.73 | CYP11B1 (0.41) | CYP3A4MEN1KMT2ALMNATDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115490668-A | Pyrimidyl imidazole compound, preparation method thereof and organic weldable protective agent | 深圳市贝加电子材料有限公司 | 2022-12-20 | — | — | CN | claimed |
| US-9540348-B2 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRYUNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-01-10 | — | — | US | claimed |
| US-20160200706-A1 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2016-07-14 | — | — | US | claimed |
| CN-117956822-A | Organic electroluminescent material and device | 环球展览公司 | 2024-04-30 | — | — | CN | disclosed |
| CN-115490668-A | Pyrimidyl imidazole compound, preparation method thereof and organic weldable protective agent | 深圳市贝加电子材料有限公司 | 2022-12-20 | — | — | CN | disclosed |
| US-9540348-B2 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRYUNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-01-10 | — | — | US | disclosed |
| US-9540348-B2 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRYUNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-01-10 | — | — | US | disclosed |
| US-9540348-B2 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRYUNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-01-10 | — | — | US | disclosed |
| US-20160200706-A1 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2016-07-14 | — | — | US | disclosed |
| US-20160200706-A1 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2016-07-14 | — | — | US | disclosed |
| US-20160200706-A1 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2016-07-14 | — | — | US | disclosed |
| WO-2005075478-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-08-18 | — | — | WO | disclosed |
| EP-1554272-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6825170-B2 | ERYTHROMYCIN TYPE MACROLIDE WITH A FUSED OXAZOLONE RING | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-11-30 | — | — | US | disclosed |
| WO-2004014900-A1 | BENZIMIDAZOLES AND BENZOTHIAZOLES AS INHIBITORS OF MAP KINASE | ELI LILLY AND COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| WO-2002094842-A2 | CONTROL OF MYOGENESIS BY MODULATION OF P38 MAP KINASE ACTIVITY | UNIVERSITY OF WESTERN ONTARIO (CA) | 2002-11-28 | — | — | WO | disclosed |
| EP-1194152-A4 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO INC (US) | 2002-11-06 | — | — | EP | disclosed |
| EP-1194152-A1 | SRC KINASE INHIBITOR COMPOUNDS | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2001000214-A1 | SRC KINASE INHIBITOR COMPOUNDS | MERCK & CO., INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| EP-0421266-A1 | Azolylpyrimidine- and -triazine derivatives and agents containing them | BASF Aktiengesellschaft (DE) | 1991-04-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200706-A1 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | BRAF, ARAF, NRAS | CYP3A4 2232/4885MEN1 1720/4885KMT2A 1523/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.